Picture of Mediwound logo

MDWD Mediwound Share Price

0.000.00%
us flag iconLast trade - 00:00
HealthcareAdventurousSmall CapMomentum Trap

Momentum

Relative Strength (%)
1m+5.01%
3m-8.11%
6m+22.54%
1yr+5.78%
Volume Change (%)
10d/3m-65.5%
Price vs... (%)
52w High-22.01%
50d MA+6.5%
200d MA+13.38%

Growth & Value

Shareholder Activity

TypeBuy / Hold / Sell
Institutions
Directors
Community

Guru Screens

Quality

NameIndustryMarket
Return on Capital-21.98%
Return on Equity-619.05%
Operating Margin-31.5%

Health Trend(F-Score)

12345678910

Bankruptcy Score(Z-Score)

Distress
Cautious
Safe

Earnings Manipulation Risk(M-Score)

Other Ratios

Leverage (ttm)Total- Intang+ Pension
Gross Gearing
Net Gearing
Cash / Assets

Recent History

Latest interim period vs. prior periodIndustryMarket
Sales Growth
EPS Growth
3yr Compound Annual Growth RateIndustryMarket
Sales CAGR
EPS CAGR
DPS CAGR

Graphical History

Revenue
Blurred out image of Revenue chart
Net Income
Blurred out image of Net Income chart
Normalised EPS
Blurred out image of Normalised EPS chart
PE Ratio Range
Blurred out image of PE Ratio Range chart
Dividend Yield Range
Blurred out image of Dividend Yield Range chart

Analyst Forecasts

Price target
( price)
31st Dec 202331st Dec 2024
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change

Analyst Consensus

Strong SellSellHoldBuyStrong Buy

EPS 2023 / 2024

Blurred out image of Mediwound EPS forecast chart

Profile Summary

Mediwound Ltd is an Israel-based biopharmaceutical company that develops, manufactures and commercializes novel, cost effective, bio-therapeutic solutions for tissue repair and regeneration. Company's portfolio is focused on next-generation protein-based therapies for burn and wound care and tissue repair and includes products such as, NexoBrid, a concentrate of proteolytic enzymes enriched in bromelain, which is an easy to use, topically-applied product that removes eschar in four hours without harming the surrounding healthy tissues.; EscharEx biological drug candidate for the debridement of chronic and other hard-to-heal wounds; MW005 a topically applied biological drug candidate for the treatment of non-melanoma skin cancers, based on the same API of NexoBrid and EscharEx products, a concentrate of proteolytic enzymes enriched in bromelain.

Directors

Last Annual
December 31st, 2022
Last Interim
December 31st, 2022
Incorporated
January 27th, 2000
Public Since
March 20th, 2014
No. of Shareholders
1
No. of Employees
73
Sector
Pharmaceuticals
Industry
Healthcare
Exchange
us flag iconNASDAQ Global Market
Shares in Issue
9,474,661

MDWD Share Price Performance

Upcoming Events for MDWD

Q1 2023 Mediwound Ltd Earnings Release

Q2 2023 Mediwound Ltd Earnings Release

Mediwound Ltd Annual Shareholders Meeting

Similar to MDWD

Picture of ADMA Biologics logo

ADMA Biologics

us flag iconNASDAQ Global Market

Picture of Alimera Sciences logo

Alimera Sciences

us flag iconNASDAQ Global Market

Picture of ANI Pharmaceuticals logo

ANI Pharmaceuticals

us flag iconNASDAQ Global Market

Picture of Aptorum logo

Aptorum

us flag iconNASDAQ Global Market

Picture of Aquestive Therapeutics logo

Aquestive Therapeutics

us flag iconNASDAQ Global Market

FAQ

Or unlock with your email

Or unlock with your email